Sponsor: Pennsylvania State University
Sponsor Study ID: BCC016
Study Title: Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
CTO #: 103371
NCT Number: NCT04696029
Phase: II
Protocol Type: Treatment
Age Group: Children
Disease Sites: Brain and Nervous System
Study Objectives: To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls.